1-2 of 2
Robert Motzer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J. Hsieh, Arif Hussain, Ulka Vaishampayan, Sandy Liu, Steven McCune, Vijay Patel, Montaser Shaheen, Johanna Bendell, Alice C. Fan, Benjamin A. Gartrell, Oscar B. Goodman, Jr, Petros G. Nikolinakos, Arash Rezazadeh Kalebasty, Yousef Zakharia, Zhentao Zhang, Hema Parmar, Lalith Akella, Keith Orford, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3248–3255.
https://doi.org/10.1158/1078-0432.CCR-22-0061
Published: 02 August 2022
View article titled, Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Open the PDF for Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial in another window
Includes: Supplementary data
Journal Articles

Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group

Judith Manola, Patrick Royston, Paul Elson, Jennifer Bacik McCormack, Madhu Mazumdar, Sylvie Négrier, Bernard Escudier, Tim Eisen, Janice Dutcher, Michael Atkins, Daniel Y.C. Heng, Toni K. Choueiri, Robert Motzer, Ronald Bukowski
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (16): 5443–5450.
https://doi.org/10.1158/1078-0432.CCR-11-0553
Published: 14 August 2011
View article titled, Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
Open the PDF for Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group in another window
Includes: Supplementary data